Cargando…
Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
CD40-stimulating immunotherapy can elicit potent anti-tumor responses by activating dendritic cells and enhancing T-cell priming. Tumor vessels orchestrate T-cell recruitment during immune response, but the effect of CD40-stimulating immunotherapy on tumor endothelial cells has not been evaluated. H...
Autores principales: | Georganaki, Maria, Ramachandran, Mohanraj, Tuit, Sander, Núñez, Nicolás Gonzalo, Karampatzakis, Alexandros, Fotaki, Grammatiki, van Hooren, Luuk, Huang, Hua, Lugano, Roberta, Ulas, Thomas, Kaunisto, Aura, Holland, Eric C, Ellmark, Peter, Mangsbo, Sara M, Schultze, Joachim, Essand, Magnus, Tugues, Sonia, Dimberg, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094447/ https://www.ncbi.nlm.nih.gov/pubmed/32231867 http://dx.doi.org/10.1080/2162402X.2020.1730538 |
Ejemplares similares
-
Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment
por: van Hooren, Luuk, et al.
Publicado: (2016) -
Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
por: Georganaki, Maria, et al.
Publicado: (2018) -
Safe engineering of CAR T cells for adoptive cell therapy of cancer using long‐term episomal gene transfer
por: Jin, Chuan, et al.
Publicado: (2016) -
Tumor angiogenesis: causes, consequences, challenges and opportunities
por: Lugano, Roberta, et al.
Publicado: (2019) -
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
por: van Hooren, Luuk, et al.
Publicado: (2021)